Added to YB: 2026-01-15
Pitch date: 2026-01-13
VKTX [bullish]
Viking Therapeutics, Inc.
+11.89%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$3.6B
Pitch Price
$30.69
Price Target
110.00 (+220%)
Dividend
N/A
EV/EBITDA
-10.48
P/E
-14.98
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Alpha Talon Investment Research Analysis of the 44th Annual J.P.Morgan Healthcare Conference - Viking Therapeutics, Inc.
VKTX: Late-stage obesity challenger with VK2735 showing superior PK profile vs tirzepatide in primates (40% better weight loss). Oral form achieved 12% weight loss in 13wks with durability post-cessation. Injectable hit 15% reduction with 90% maintenance. $700M cash, maintenance study Q2-Q3 2026. $110 PT.
Read full article (5 min)